Ignite Creation Date:
2025-12-24 @ 5:01 PM
Ignite Modification Date:
2026-01-05 @ 5:40 PM
Study NCT ID:
NCT05394350
Status:
TERMINATED
Last Update Posted:
2024-11-08
First Post:
2022-05-23
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-07-07
Start Date Type:
ACTUAL
Primary Completion Date:
2023-09-07
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-09-07
Completion Date Type:
ACTUAL
First Submit Date:
2022-05-23
First Submit QC Date:
None
Study First Post Date:
2022-05-27
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2024-08-19
Results First Submit QC Date:
None
Results First Post Date:
2024-10-04
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-11-07
Last Update Post Date:
2024-11-08
Last Update Post Date Type:
ACTUAL